Guidelines for acute management of hyperammonemia in the Middle East region

Majid Alfadhel, Fuad Al Mutairi, Nawal Makhseed, Fatma Al Jasmi, Khalid Al-Thihli, Emtithal Al-Jishi, Moeenaldeen AlSayed, Zuhair N. Al-Hassnan, Fathiya Al-Murshedi, Johannes Häberle, Tawfeg Ben-Omran, Middle East Hyperammonemia and Urea Cycle Disorders Scientific Group (MHUSG)

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Hyperammonemia is a life-threatening event that can occur at any age. If treated, the early symptoms in all age groups could be reversible. If untreated, hyperammonemia could be toxic and cause irreversible brain damage to the developing brain. Objective: There are major challenges that worsen the outcome of hyperammonemic individuals in the Middle East. These include: lack of awareness among emergency department physicians about proper management of hyperammonemia, strained communication between physicians at primary, secondary, and tertiary hospitals, and shortage of the medications used in the acute management of hyperammonemia. Therefore, the urge to develop regional guidelines is extremely obvious. Method: We searched PubMed and Embase databases to include published materials from 2011 to 2014 that were not covered by the European guidelines, which was published in 2012. We followed the process of a Delphi conference and involved one preliminary meeting and two follow-up meetings with email exchanges between the Middle East Hyperammonemia and Urea Cycle Disorders Scientific Group regarding each draft of the manuscript. Results and discussion: We have developed consensus guidelines based on the highest available level of evidence. The aim of these guidelines is to homogenize and harmonize the treatment protocols used for patients with acute hyperammonemia, and to provide a resource to not only metabolic physicians, but also physicians who may come in contact with individuals with acute hyperammonemia. Conclusion: These suggested guidelines aim to ease the challenges faced by physicians dealing with acute hyperammonemia in the region. In addition, guidelines have demonstrated useful collaboration between experts in the region, and provides information that will hopefully improve the outcomes of patients with acute hyperammonemia.

Original languageEnglish
Pages (from-to)479-487
Number of pages9
JournalTherapeutics and Clinical Risk Management
Volume12
DOIs
Publication statusPublished - Mar 31 2016

Fingerprint

Hyperammonemia
Middle East
Brain
physician
Guidelines
Poisons
Electronic mail
management
Urea
Physicians
Communication
brain damage
shortage
Inborn Urea Cycle Disorder
age group
brain
medication
contact
expert
Manuscripts

Keywords

  • Acute management
  • Ammonia
  • Hyperammonemia
  • Inborn errors of metabolism
  • Middle East
  • Urea cycle

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Alfadhel, M., Al Mutairi, F., Makhseed, N., Al Jasmi, F., Al-Thihli, K., Al-Jishi, E., ... Middle East Hyperammonemia and Urea Cycle Disorders Scientific Group (MHUSG) (2016). Guidelines for acute management of hyperammonemia in the Middle East region. Therapeutics and Clinical Risk Management, 12, 479-487. https://doi.org/10.2147/TCRM.S93144

Guidelines for acute management of hyperammonemia in the Middle East region. / Alfadhel, Majid; Al Mutairi, Fuad; Makhseed, Nawal; Al Jasmi, Fatma; Al-Thihli, Khalid; Al-Jishi, Emtithal; AlSayed, Moeenaldeen; Al-Hassnan, Zuhair N.; Al-Murshedi, Fathiya; Häberle, Johannes; Ben-Omran, Tawfeg; Middle East Hyperammonemia and Urea Cycle Disorders Scientific Group (MHUSG).

In: Therapeutics and Clinical Risk Management, Vol. 12, 31.03.2016, p. 479-487.

Research output: Contribution to journalArticle

Alfadhel, M, Al Mutairi, F, Makhseed, N, Al Jasmi, F, Al-Thihli, K, Al-Jishi, E, AlSayed, M, Al-Hassnan, ZN, Al-Murshedi, F, Häberle, J, Ben-Omran, T & Middle East Hyperammonemia and Urea Cycle Disorders Scientific Group (MHUSG) 2016, 'Guidelines for acute management of hyperammonemia in the Middle East region', Therapeutics and Clinical Risk Management, vol. 12, pp. 479-487. https://doi.org/10.2147/TCRM.S93144
Alfadhel, Majid ; Al Mutairi, Fuad ; Makhseed, Nawal ; Al Jasmi, Fatma ; Al-Thihli, Khalid ; Al-Jishi, Emtithal ; AlSayed, Moeenaldeen ; Al-Hassnan, Zuhair N. ; Al-Murshedi, Fathiya ; Häberle, Johannes ; Ben-Omran, Tawfeg ; Middle East Hyperammonemia and Urea Cycle Disorders Scientific Group (MHUSG). / Guidelines for acute management of hyperammonemia in the Middle East region. In: Therapeutics and Clinical Risk Management. 2016 ; Vol. 12. pp. 479-487.
@article{81084c37f0334b509272025a07c52d68,
title = "Guidelines for acute management of hyperammonemia in the Middle East region",
abstract = "Background: Hyperammonemia is a life-threatening event that can occur at any age. If treated, the early symptoms in all age groups could be reversible. If untreated, hyperammonemia could be toxic and cause irreversible brain damage to the developing brain. Objective: There are major challenges that worsen the outcome of hyperammonemic individuals in the Middle East. These include: lack of awareness among emergency department physicians about proper management of hyperammonemia, strained communication between physicians at primary, secondary, and tertiary hospitals, and shortage of the medications used in the acute management of hyperammonemia. Therefore, the urge to develop regional guidelines is extremely obvious. Method: We searched PubMed and Embase databases to include published materials from 2011 to 2014 that were not covered by the European guidelines, which was published in 2012. We followed the process of a Delphi conference and involved one preliminary meeting and two follow-up meetings with email exchanges between the Middle East Hyperammonemia and Urea Cycle Disorders Scientific Group regarding each draft of the manuscript. Results and discussion: We have developed consensus guidelines based on the highest available level of evidence. The aim of these guidelines is to homogenize and harmonize the treatment protocols used for patients with acute hyperammonemia, and to provide a resource to not only metabolic physicians, but also physicians who may come in contact with individuals with acute hyperammonemia. Conclusion: These suggested guidelines aim to ease the challenges faced by physicians dealing with acute hyperammonemia in the region. In addition, guidelines have demonstrated useful collaboration between experts in the region, and provides information that will hopefully improve the outcomes of patients with acute hyperammonemia.",
keywords = "Acute management, Ammonia, Hyperammonemia, Inborn errors of metabolism, Middle East, Urea cycle",
author = "Majid Alfadhel and {Al Mutairi}, Fuad and Nawal Makhseed and {Al Jasmi}, Fatma and Khalid Al-Thihli and Emtithal Al-Jishi and Moeenaldeen AlSayed and Al-Hassnan, {Zuhair N.} and Fathiya Al-Murshedi and Johannes H{\"a}berle and Tawfeg Ben-Omran and {Middle East Hyperammonemia and Urea Cycle Disorders Scientific Group (MHUSG)}",
year = "2016",
month = "3",
day = "31",
doi = "10.2147/TCRM.S93144",
language = "English",
volume = "12",
pages = "479--487",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Guidelines for acute management of hyperammonemia in the Middle East region

AU - Alfadhel, Majid

AU - Al Mutairi, Fuad

AU - Makhseed, Nawal

AU - Al Jasmi, Fatma

AU - Al-Thihli, Khalid

AU - Al-Jishi, Emtithal

AU - AlSayed, Moeenaldeen

AU - Al-Hassnan, Zuhair N.

AU - Al-Murshedi, Fathiya

AU - Häberle, Johannes

AU - Ben-Omran, Tawfeg

AU - Middle East Hyperammonemia and Urea Cycle Disorders Scientific Group (MHUSG)

PY - 2016/3/31

Y1 - 2016/3/31

N2 - Background: Hyperammonemia is a life-threatening event that can occur at any age. If treated, the early symptoms in all age groups could be reversible. If untreated, hyperammonemia could be toxic and cause irreversible brain damage to the developing brain. Objective: There are major challenges that worsen the outcome of hyperammonemic individuals in the Middle East. These include: lack of awareness among emergency department physicians about proper management of hyperammonemia, strained communication between physicians at primary, secondary, and tertiary hospitals, and shortage of the medications used in the acute management of hyperammonemia. Therefore, the urge to develop regional guidelines is extremely obvious. Method: We searched PubMed and Embase databases to include published materials from 2011 to 2014 that were not covered by the European guidelines, which was published in 2012. We followed the process of a Delphi conference and involved one preliminary meeting and two follow-up meetings with email exchanges between the Middle East Hyperammonemia and Urea Cycle Disorders Scientific Group regarding each draft of the manuscript. Results and discussion: We have developed consensus guidelines based on the highest available level of evidence. The aim of these guidelines is to homogenize and harmonize the treatment protocols used for patients with acute hyperammonemia, and to provide a resource to not only metabolic physicians, but also physicians who may come in contact with individuals with acute hyperammonemia. Conclusion: These suggested guidelines aim to ease the challenges faced by physicians dealing with acute hyperammonemia in the region. In addition, guidelines have demonstrated useful collaboration between experts in the region, and provides information that will hopefully improve the outcomes of patients with acute hyperammonemia.

AB - Background: Hyperammonemia is a life-threatening event that can occur at any age. If treated, the early symptoms in all age groups could be reversible. If untreated, hyperammonemia could be toxic and cause irreversible brain damage to the developing brain. Objective: There are major challenges that worsen the outcome of hyperammonemic individuals in the Middle East. These include: lack of awareness among emergency department physicians about proper management of hyperammonemia, strained communication between physicians at primary, secondary, and tertiary hospitals, and shortage of the medications used in the acute management of hyperammonemia. Therefore, the urge to develop regional guidelines is extremely obvious. Method: We searched PubMed and Embase databases to include published materials from 2011 to 2014 that were not covered by the European guidelines, which was published in 2012. We followed the process of a Delphi conference and involved one preliminary meeting and two follow-up meetings with email exchanges between the Middle East Hyperammonemia and Urea Cycle Disorders Scientific Group regarding each draft of the manuscript. Results and discussion: We have developed consensus guidelines based on the highest available level of evidence. The aim of these guidelines is to homogenize and harmonize the treatment protocols used for patients with acute hyperammonemia, and to provide a resource to not only metabolic physicians, but also physicians who may come in contact with individuals with acute hyperammonemia. Conclusion: These suggested guidelines aim to ease the challenges faced by physicians dealing with acute hyperammonemia in the region. In addition, guidelines have demonstrated useful collaboration between experts in the region, and provides information that will hopefully improve the outcomes of patients with acute hyperammonemia.

KW - Acute management

KW - Ammonia

KW - Hyperammonemia

KW - Inborn errors of metabolism

KW - Middle East

KW - Urea cycle

UR - http://www.scopus.com/inward/record.url?scp=84962376174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962376174&partnerID=8YFLogxK

U2 - 10.2147/TCRM.S93144

DO - 10.2147/TCRM.S93144

M3 - Article

AN - SCOPUS:84962376174

VL - 12

SP - 479

EP - 487

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

ER -